C12N 2750/14222
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/14222 (New viral proteins or individual genes, new structural or functional aspects of) appears on 22 US grants and 19 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 19
- Assignees
- 18
- Inventors
- 44
- Latest grant
- 18 May 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 2 | 1 |
| 2003 | 1 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 2 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 1 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 2 | 2 |
| 2018 | 1 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 3 |
By publication year. Applications have been published since 2001.
Recent patents
- Compositions and methods for treating, including preventing, parvovirus infections and related diseases18 May 2021US 11,008,367 B2University of Louisville Research Foundation, Inc.
- Compositions and methods for treating, including preventing, parvovirus infections and related diseases26 Feb 2019US 10,214,565 B2University of Louisville Research Foundation, Inc.
- Parvovirus Vp1 unique region polypeptides and compositions thereof24 Jul 2018US 10,030,052 B2Glaxosmithkline Biologicals SA
- Method for generating a parvovirus B19 virus-like particle29 Aug 2017US 9,744,228 B2Norvartis AG
- Modified VP1-capsid protein of parvovirus B1921 Feb 2017US 9,573,979 B2
- Erythroparvovirus compositions and methods for gene therapy16 Oct 2025US 2025/0320521 A1Synteny Therapeutics, Inc.
- Erythroparvovirus with a modified genome for gene therapy2 Oct 2025US 2025/0302994 A1Synteny Therapeutics, Inc.
- Erythroparvovirus with a modified capsid for gene therapy25 Sep 2025US 2025/0295810 A1Synteny Therapeutics, Inc.
- Baculovirus expression system5 Sep 2024US 2024/0294940 A1Bioverativ Therapeutics Inc.
- Novel erythroparvovirus associated with respiratory distress in equine26 Oct 2023US 2023/0340032 A1Intervet Inc.
Most cited
By later US patents
- Virus vectors and methods of making and administering the same197US 7,172,893 B2The University of North Carolina at Chapel Hill · 2007
- Recombinant parvovirus vectors and method of making167US 6,491,907 B1The University of North Carolina at Chapel Hill · 2002
- Methods for adapting nucleic acid for detection, sequencing, and cloning using exonuclease22US 5,518,901 A1996
- Methods for nucleic acid detection, sequencing, and cloning using exonuclease21US 5,744,306 AEmory University · 1998
- B19 parvovirus capsids17US 5,508,186 AThe United States of America as represented by the Secretary of Health and Human Services · 1996